Accropeutics secured $12 million in Series B Plus financing led by Shenzhen Capital Group. The funds will support the generation of clinical data for their lead therapeutic AC-101 in an ongoing Phase Ib trial.
Amount Raised
$12 Million
Round Type
Series B
Investors
Description
Accropeutics Inc., a clinical-stage biotechnology company, announced the closing of its $12 million Series B Plus financing. The round was led by Shenzhen Capital Group with participation from Morningside Ventures, Leader Venture Investment, and Hefei Sci-Tec Venture Capital. The funding will be used to generate more clinical data for AC-101, a RIPK2 inhibitor for Ulcerative Colitis. Accropeutics is committed to advancing its innovative therapies for immune mediated diseases.
Quick answer
Accropeutics raised $12 Million in a Series B round, dated March 14, 2025. Investors: Hefei Sci Tec Venture Capital, Leader Venture Investment, Morningside Ventures and Shenzhen Capital Group. Accropeutics is based in Suzhou, Jiangsu, China.
- How much did Accropeutics raise?
- Accropeutics raised $12 Million in a Series B round on March 14, 2025.
- Who invested in Accropeutics?
- Hefei Sci Tec Venture Capital, Leader Venture Investment, Morningside Ventures and Shenzhen Capital Group are named as investors in this round.
- What does Accropeutics do?
- Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms..
- Where is Accropeutics based and how big is it?
- Accropeutics is based in Suzhou, Jiangsu, China.
- Who are the decision-makers at Accropeutics?
- Fundz holds 2 contacts at Accropeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Accropeutics that raised within 45 days of this round, from Fundz verified event records.
- Cycuria Therapeutics raised an undisclosed amount (Grant) on April 28, 2025.
- Oratech Pharmaceuticals raised $37M (Corporate Round) on April 28, 2025.
- Avidicure raised $50M (Seed) on April 27, 2025.
- Granite Bio raised $100M (Series A) on April 25, 2025.
- CERo Therapeutics Holdings raised $5M on April 22, 2025.
- Retension Pharmaceuticals raised $12M on April 22, 2025.
Who to call at Accropeutics, and when
A new round usually means Accropeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Accropeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Accropeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Accropeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Accropeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAccropeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.